systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-750Research ArticleСТАТЬИARTICLESПациент с артериальной гипертензией и ассоциированными клиническими состояниями: вопросы леченияКислякО. А.noemail@neicon.ruЛеонтьеваМ. С.noemail@neicon.ruГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова, МоскваRussian Federation201209022023931417Copyright © Кисляк О.А., Леонтьева М.С., 20232023Кисляк О.А., Леонтьева М.С.Кисляк О.А., Леонтьева М.С.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/750ReferencesДиагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (4-й пересмотр). Системные гипертензии 2010; 3: 5-26.Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (4-й пересмотр). Системные гипертензии 2010; 3: 5-26.Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8: 30-41.Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8: 30-41.Fonarow GC. Improving quality of care and outcomes for heart failure. Role of registries. Circulation J 2011; 75: 1783-90.Fonarow GC. Improving quality of care and outcomes for heart failure. Role of registries. Circulation J 2011; 75: 1783-90.ƠConnor CM,Whewllan DJ, Wojdyla D et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction. The HF-ACTION predictive risk score model. Circulation Heart failure 2012; 5: 63-71.ƠConnor CM,Whewllan DJ, Wojdyla D et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction. The HF-ACTION predictive risk score model. Circulation Heart failure 2012; 5: 63-71.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J doi: 10.1093 /eurheartj/ehs 104.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J doi: 10.1093 /eurheartj/ehs 104.Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136; doi: 10.1093/eurheartj/ehl 260.Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136; doi: 10.1093/eurheartj/ehl 260.Gillespie E, White C, Kardas M et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28: 2261-6.Gillespie E, White C, Kardas M et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28: 2261-6.Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51 (2): 393-8.Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51 (2): 393-8.Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30 (10): 1203-12.Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30 (10): 1203-12.De Rosa ML. Cardio classics revisited - focus on the role of candesartan. Vas Health and Risk management 2010; 6: 1047-63.De Rosa ML. Cardio classics revisited - focus on the role of candesartan. Vas Health and Risk management 2010; 6: 1047-63.Чазова И.Е., Ратова Л.Г. Первое поколение сартанов: есть ли перспективы. Системные гипертензии. 2010; 4: 3-7.Чазова И.Е., Ратова Л.Г. Первое поколение сартанов: есть ли перспективы. Системные гипертензии. 2010; 4: 3-7.
The authors declare that there are no conflicts of interest present.